Global Markets for Emerging Insulin Drug and Delivery Technologies
Report Highlights
The global market for insulin drug and delivery devices totaled $24 billion in 2012. The overall insulin drug and device market is projected to be worth $25.7 billion by 2013 and $40.2 billion by 2018, a five-year compound annual growth rate (CAGR) for of 9.3% from 2013 to 2018.
This report provides:
- An overview of global insulin drugs and delivery in pharmaceutical and biotechnology markets with classification and usage in diabetes types.
- Analyses of global market trends, with data from 2011 and 2012, estimates for 2013 and 2018 and projections of compound annual growth rates (CAGRs) through 2018.
- Discussion of the market segmented by insulin syringes and vials, and insulin pens and insulin pumps.
- Evaluation of emerging technologies in the insulin drug and delivery field that have potential in the diabetes market, with improved glucose control, along with improved and well-accepted newer delivery methods.
- Patent identifications for insulin as a drug, along with its delivery methods.
SCOPE OF THE STUDY
The scope of this study encompasses insulin drugs and delivery in pharmaceutical and biotechnology markets with its classification and its usage in diabetes types. BCC analyzes each market and its applications, as well as its regulatory environment, technology and market share. The markets, such as type 1 diabetes, type 2 diabetes and gestational diabetes, are analyzed for the years 2011 and 2012. The markets are projected through the end of 2013 and for a five-year period until 2018.
The market is also segmented by insulin syringes and vials, insulin pens and insulin pumps. Technological issues include the latest trends and developments. The study also includes the patent identifications for insulin as a drug, along with its deliveries.
The emerging markets for insulin drug and delivery include India, China, Japan, Korea, Taiwan, Canada, Africa, Australia and New Zealand.
Analyst Credentials
Shalini Shahani Dewan focuses on pharmaceuticals and biotechnology and has been a BCC Research contributor since 2002 as both an analyst and project manager. She has explored a wide range of topics and companies, including working for Johnson & Johnson doing market surveillance. She has an undergraduate degree in pharmacy and master's degree in medicinal chemistry. She resides in the Bay Area.
